$10k each for 100 + x-rays plus independent evaluation of the combined data as a group and made into a presentation quality report. Probably. AGN has been pretty good with our money and more successful at completing the COVID trial as any I that have seen. I agree with CM/Smoki, data asap and supplementary data to expound on possible successful WHO scores.
I feel the delay in IPF/CC is partially the result of the attention the COVID Trial has taken.* Two (+) lung specific CTs with overlapping results is how Gilead/Rem pushed through their limited results for EUA, and lots of cash to dominate a large portion of available Trial sites. I posted their CT results and asked experts here to discuss the results/ P-values / safety. Obviously AGN does not have those resources.
OAN, US COVID cases have dropped but World cases are increasing back to over 500k average again.
Besides BOTH South Korea and Australia were being leaders in suppressing COVID and those countries ability's to Isolate their populations certainly helped them. Just too few patients. Yes 20 patients, but X $25k would have sapped the COVID effort.
The WHO scores for COVID may reflect similar results as the IPF/CC Trial, IMO
" Primary Outcome Measures :
A ≥50% reduction in the average number of coughs per hour over 24 hours comparing baseline to treatment period using an ambulatory cough monitor [ Time Frame: Baseline and week 12 (≥11 weeks of treatment) ]
No worsening of force vital capacity (FVC) in either mL or % predicted [ Time Frame: Baseline and week 12 (≥11 weeks of treatment) ]
YES these longer term data points and treatments would be GREAT info. But, $$.
...GLTA...
